Möchten Sie immer auf dem neuesten Stand bleiben?

Carlsbad, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious...

- Company’s co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding as part of previously announced grant from the US Crohn’s and Colitis Foundation - Lead program, PALI-2108 for...

– Transformational transaction jumpstarts development pipeline into high-value inflammatory bowel disease (IBD) market – Lead program, PALI-2108, oral prodrug therapy for the treatment...

Live moderated webcast with J.D. Finley, Chief Executive Officer of Palisade Bio on Wednesday, October 25th at 2:00 PM ET Carlsbad, CA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq:...

Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is...

Announces Awarding of Inducement Grant to New Chief Medical Officer Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a...

Carlsbad, CA, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is...

– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing expected by Q3 2024 – Inflammatory bowel...

– Company accelerating late-stage corporate development activities to in-license/acquire synergistic assets to build GI-focused pipeline – Strong financial position with cash to fund...

– Study did not achieve primary efficacy endpoint of reducing adhesions in LB1148 treated patients compared to placebo treated patients post bowel resection surgery Carlsbad, CA, Aug. 09, 2023 ...